Normal Saline Versus Heparin Intermittent Flushing for the Prevention of Occlusion in Port-a-Cath: Randomized Controlled Trial
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 192
- 主要终点
- port-a-cath infection
研究概览
简要总结
Purpose:
An evidence implementation of a randomized controlled trial for whether there is the difference in intermittent flushing 0.9% normal saline and heparin? Design: a single-blind randomized controlled trial
Method:
This study is based on the 5A (Ask, Acquire, Appraise, Apply, Audit) of evidence health care step, and design randomized controlled trial for evidence implementation.
We will include inpatients over 20 years-old adults in New Taipei City TuCheng Hospital, Taiwan, who need administration medicine by port-a-catcher. The sample size is 192 according to G-power software. Random allocation software has using for block randomization, would assign to group A: flushing with 0.9% normal saline 10ml, group B: flushing with 0.9% normal saline 20ml, and group C: flushing with heparin 100 USP/ml. SPSS 20.0 software for statistical analysis, mean or standard deviation, one- way ANOVA would use.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 20 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Non-pediatric inpatients over 20 years of age with PAC placed for any disease and who need medication during hospitalization.
排除标准
- •History of PAC obstruction, continuous high volume drip via PAC, taking anticoagulant or antiplatelet agents, abnormal blood coagulation, pregnancy or contraceptive use, specified flushing solution by case
研究组 & 干预措施
Normal saline 10 ml
干预措施: Normal Saline Flush 10 ml (Drug)
Normal saline 20 ml
干预措施: Normal Saline Flush 20 ml (Drug)
usual care (heparin)
干预措施: Heparin Flush (1000 USP, 10ml) (Drug)
结局指标
主要结局
port-a-cath infection
时间窗: in hospitalized (during admission), up to 12 weeks
blood culture from port-A show bacterial growth
port-a-cath occlusion
时间窗: in hospitalized (during admission), up to 12 weeks
failure to infusion fluid
次要结局
未报告次要终点
